TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022
TRACON Pharmaceuticals (TCON) announced it will report its fourth quarter and full year 2021 financial results on March 15, 2022, after U.S. market close. Management will host a conference call the same day at 4:30 PM ET to update corporate activities and discuss results. TRACON focuses on developing targeted cancer therapeutics through a cost-efficient, CRO-independent platform, partnering with companies outside the U.S. for development and commercialization in the U.S.
- Plans to report Q4 and full year 2021 financial results, indicating upcoming transparency for investors.
- Active corporate development strategy seeking partnerships for U.S. commercialization, which could reduce financial risk.
- None.
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States, announced today that it will report its fourth quarter and full year 2021 financial and operating results after the close of U.S. financial markets on Tuesday, March 15, 2022. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
| Conference call and webcast: | |
| Date: | March 15, 2022 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 4073534 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | (212) 915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
When will TRACON Pharmaceuticals report its Q4 2021 financial results?
What time is the TRACON Pharmaceuticals conference call on March 15, 2022?
What is the focus of TRACON Pharmaceuticals?
How can I access the TRACON Pharmaceuticals conference call?
